Krishna Kumari P, Siddharth Reddy Chiteti, Vinay K Aileni, Sudhir Babji, William C Blackwelder, Ashok Kumar, Jayant Vagha, Uma Nayak, Monjori Mitra, Narayanaappa D, Sonali Kar, Sangeeta Yadav, Swamy Naidu, Niranjan Mahantshetti, Vasant Khalatkar, Satyajit Mohapatra, P K Purthi, Pawan Sharma, A Kannan, Ramchandra Keshav Dhongade, Sai D Prasad, Raches Ella, Krishna Mohan Vadrevu
The WHO pre-qualified rotavirus vaccine, ROTAVAC®, is derived naturally from the neonatal 116E rotavirus strain, and stored at -20°C. As refrigerator storage is preferable, immunogenicity and safety of liquid formulations kept at 2-8°C, having excipients to stabilize the rotavirus, with or without buffers, were compared with ROTAVAC® in different clinical studies. Study-1, the pivotal trial for this entire product development work, was a randomized, single-blind trial with two operationally seamless phases: (i) an exploratory phase involving 675 infants in which two formulations, ROTAVAC 5C (LnHRV-1...
December 15, 2023: Human Vaccines & Immunotherapeutics